0001181431-12-002291.txt : 20120111 0001181431-12-002291.hdr.sgml : 20120111 20120111180310 ACCESSION NUMBER: 0001181431-12-002291 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20111220 FILED AS OF DATE: 20120111 DATE AS OF CHANGE: 20120111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP CENTRAL INDEX KEY: 0000911326 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 561808663 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SPRING STREET STREET 2: SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: (781) 357-9900 MAIL ADDRESS: STREET 1: 128 SPRING STREET STREET 2: SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: TRIMERIS INC DATE OF NAME CHANGE: 19970516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAVIS STEPHEN CENTRAL INDEX KEY: 0001131146 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-23155 FILM NUMBER: 12522878 MAIL ADDRESS: STREET 1: NEUROGEN CORP STREET 2: 35 NORTHEAST INDUSTRIAL RD CITY: BRANFORD STATE: CT ZIP: 06405 4/A 1 rrd329610.xml DAVIS 122011 FORM 4/A X0304 4/A 2011-12-20 2011-12-22 0 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001131146 DAVIS STEPHEN SYNAGEVA BIOPHARMA CORP. 128 SPRING ST STE 520 LEXINGTON MA 02421 1 0 0 0 Stock Option (Right to Buy) 23.00 2011-12-20 4 A 0 15000 0.00 A 2021-12-19 Common Stock 15000 15000 D This amendment is filed solely to correct a clerical error in the initial filing. In this regard the number of options acquired was incorrectly included in the disposition column rather than the acquisition column. 1/36 of the shares subject to this option vest and become exercisable on December 2, 2011 and monthly thereafter. /s/ Marc A. Rubenstein, Attorney-in-Fact 2012-01-11 EX-24. 2 rrd295247_333955.htm DAVIS POA rrd295247_333955.html 

POWER OF ATTORNEY

	Know all by these presents, that the undersigned hereby constitutes and appoints each of Sanj K. Patel
 and Marc A Rubenstein, signing singly, as the undersigned's true and lawful attorney-in-fact to:

	(1)	execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or
	 director of Synageva BioPharma Corp. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a)
	of the Securities Exchange Act of 1934, as amended (the "Act"), and the rules thereunder;

	(2)	do and perform any and all acts for and on behalf of the undersigned which may be necessary or
	desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States
	Securities and Exchange Commission and any stock exchange or similar authority; and

	(3)	take any other action of any type whatsoever in connection with the foregoing which, in the
	 opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by,
	 the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of
	the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and
	 conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

	The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform any and
	 every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the
	 rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could
	 do if personally present, with full power of substitution or revocation, hereby ratifying and confirming
	 all the acts such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of
	 attorney and the rights and powers herein granted.  The undersigned acknowledges that each of the
	 foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not
	 assuming any of the undersigned's responsibilities to comply with Section 16 of the Act.

	This Power of Attorney shall remain in full force and effect until the undersigned is no longer required
	 to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities
	 issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each
	 of the foregoing attorneys-in-fact.


	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be

executed as of this 20th day of December, 2011.



               	By:
/s/ Stephen Davis

	Print Name:
Stephen Davis